iShares Biotechnology ETF
887 hedge funds and large institutions have $5.28B invested in iShares Biotechnology ETF in 2024 Q2 according to their latest regulatory filings, with 78 funds opening new positions, 201 increasing their positions, 329 reducing their positions, and 64 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
887
Holders Change
-4
Holders Change %
-0.45%
% of All Funds
12.9%
Holding in Top 10
11
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.16%
New
78
Increased
201
Reduced
329
Closed
64
Calls
$301M
Puts
$1.27B
Net Calls
-$972M
Net Calls Change
-$125M
Top Buyers
| 1 |
Jane Street
New York
|
+$121M |
| 2 |
Citigroup
New York
|
+$68.9M |
| 3 |
JPMorgan Chase & Co
New York
|
+$54.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$29.9M |
| 5 |
Two Sigma Investments
New York
|
+$15.9M |
Top Sellers
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$91.5M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$72.8M |
| 3 |
Millennium Management
New York
|
-$39.7M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$29.4M |
| 5 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
-$26.7M |
